ARON 3D_Transparent

Urothelial Carcinoma

Sex ARON 2

Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab

Incorvaia L,
et al. Sci Rep.
2025
1n0qB6 VSRGWzc098ji9sg

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 

Massari F, et al.
Cancer Immunol Immunother.
2024
1733809351923

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.

Santoni M, et al.
Cancer Immunol Immunother.
2023
H7MNXe MQ0GfFaBaXYUL2w

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Fiala O, et al.
Cancer Immunol Immunother.
2023
1733692011631

Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study

Santoni M, et al.
Clin Exp Med.
2023
1731274039510

Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project 

Rizzo A, et al.
Clin Exp Metastasis.
2024

Do you want to join us ?

Join us today
ARON 3D_Transparent
Youtube Linkedin

Coordinated and designed by Atteggiamento Digitale .

Legal and Privacy.